iPS Cells & Regenerative Medicine– category –
-
Tempest Therapeutics to Advance In Vivo CAR T-Cell Therapy TPST-4003 into Clinical Trials by Year-End for Autoimmune Diseases like Myasthenia Gravis and Multiple Sclerosis
Biotech News Portal USA Overview Tempest Therapeutics announced on July 16, 2026, that its lead in vivo CAR T-cell product candidate, TPST-4003, is slated to enter clinical trials by year-end. This candidate will be evaluated in investig... -
CRISPR Gene Editing Therapy Trials Surge to Over 100 Globally, Demonstrating High Precision and Efficacy for Genetic Disorders like Sickle Cell Disease
SciHive USA Overview As of 2026, clinical trials for CRISPR gene-editing therapies have surged to over 100 globally, attracting significant anticipation for their potential to treat various diseases. A recent report by NVIDIA highlights ... -
South Korea Eases Regulations for Autologous Advanced Regenerative Medicine, Expediting Clinical Entry for NK Cell Therapies by Downgrading Risk Classification
Clipart Korea - Seoul Economic Daily Finance News from South Korea South Korea Overview On July 17, 2026, the South Korean government announced significant deregulation for advanced regenerative medicine utilizing patients' own immune ce... -
Sana Biotechnology Announces Groundbreaking 14-Month Durability Data for Hypoimmune-Modified Islet Cell Transplantation (UP421) in Type 1 Diabetes Without Immunosuppression, Published in The New England Journal of Medicine
GlobeNewswire (Sana Biotechnology) USA Overview Sana Biotechnology announced groundbreaking long-term durability data for its hypoimmune-modified islet cell transplant UP421 in Type 1 Diabetes patients, demonstrating 14 months of sustain... -
Beyond RNA: DNA-Guided CRISPR Heralds a New Era of Precision Gene Editing
Liv Hospital Turkey Overview Liv Hospital reports a significant shift in CRISPR gene editing, moving from conventional RNA-guided to potentially more stable and precise DNA-guided systems. This evolution, coupled with advancements in del... -
Space-Grown Organoids and Proteomics Synergize to Advance Human Disease Research for Complex Conditions like Retrosyndromes and Cancer
Scientific News Outlet USA Overview On July 17, 2026, the fusion of space-grown organoids and proteomics technology was reported to be significantly advancing research into complex human diseases such as retrosyndromes and cancer. Organo... -
NIH-Funded Team Discovers Miniaturized CRISPR Enzyme Al3Cas12f, Enabling Precision In Vivo Gene Delivery via AAV Vectors
National Institutes of Health (NIH) USA Overview An NIH-funded research team has discovered a novel, enhanced miniaturized CRISPR gene-editing system, a natural enzyme named 'Al3Cas12f,' capable of targeted in vivo delivery. This enzyme ... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
Century Therapeutics Unveils Preclinical Data for iPSC-Derived Islet Replacement Therapy CNTY-813 for Type 1 Diabetes, Aiming for Immunosuppression-Free Treatment via Allo-Evasion™ 5.0 Technology and H2 2026 IND Filing
GlobeNewswire (Century Therapeutics) USA Overview Century Therapeutics announced that preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, will be presented at EASD 2026 and the Breakthrough T1D ... -
CAR T-Cell Therapy Broadens Horizons: Expanding Indications and Manufacturing Advances Drive Wider Access Beyond Oncology to Autoimmune Diseases
AJMC USA Overview This review article comprehensively discusses how CAR T-cell therapy is entering an era of broader adoption, driven by clinical advancements, expanding indications, and enhanced manufacturing efficiency. Building on ini...
